Defibrotide mitigates endothelial cell injury induced by plasmas from patients with COVID-19 and related vasculopathies
Description
CONCLUSION: Our data, in the context of a recent clinical trial in severe COVID-19, suggest benefits to further exploration of defibrotide and these pathways in COVID-19 and related endotheliopathies.
